Axogen, Inc.

NasdaqCM:AXGN 株式レポート

時価総額：US$2.3b

Axogen 配当と自社株買い

配当金 基準チェック /06

Axogen配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-6.0%

バイバック利回り

総株主利回り-6.0%
将来の配当利回りn/a
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78

Apr 30
Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78

AXGN: BLA Approval And Market Expansion Will Shape Balanced Risk Reward Outlook

Narrative Update on Axogen Axogen's updated fair value estimate has moved by about $0.67, with analysts pointing to higher price targets around $40 to $42, supported by Avance Nerve Graft's FDA BLA approval, broader market expansion plans, and recent coverage highlighting its differentiated position in peripheral nerve repair. Analyst Commentary Recent research commentary on Axogen has focused heavily on the FDA BLA approval for Avance Nerve Graft, higher price targets around the low $40 range, and the company’s focus on expanding into new clinical markets.

AXGN: BLA Approval Will Support Broader Peripheral Nerve Repair Adoption

Narrative Update on Axogen Axogen's analyst price targets have shifted higher into the low $40s, with analysts pointing to recent FDA BLA approval for Avance Nerve Graft, broader market expansion plans, and reduced risk following an equity raise as key supports for their updated views. Analyst Commentary Recent research on Axogen has centered on the FDA BLA approval for Avance Nerve Graft, the equity raise, and the company’s focus on peripheral nerve repair.

AXGN: BLA Approval Should Support Wider Nerve Repair Market Adoption

Analysts have nudged Axogen's fair value estimate higher, with the blended price target moving from about $39.20 to roughly $40.56 as recent FDA BLA approval for Avance Nerve Graft and broader market expansion potential support more constructive views on growth and profitability. Analyst Commentary Recent research updates cluster around a more constructive view of Axogen following FDA BLA approval for Avance Nerve Graft and a clearer path to broader market coverage and adoption.

AXGN: BLA Approval And Equity Raise Will Support 2026 Nerve Repair Rollout

Axogen's analyst price target moves higher, with recent Street research pointing to a range of $40 to $42 as analysts highlight the FDA BLA approval for Avance Nerve Graft, expanded market opportunities, and expectations for sustained revenue growth and improving profitability. Analyst Commentary Recent research updates cluster around the FDA BLA approval for Avance Nerve Graft and how it could influence Axogen's growth, profitability, and valuation over time.

AXGN: Follow On Equity Raises Will Support Bullish 2025 Outlook

Analysts have slightly trimmed their average price target for Axogen, now reflecting a modestly lower assumed future P/E multiple while keeping fair value estimates around $37.33 and making only marginal adjustments to the discount rate, revenue growth, and profit margin assumptions. What's in the News Axogen filed a follow on equity offering of up to $85 million in common stock, providing additional access to equity capital if the company chooses to proceed with the full amount.

AXGN: FDA Approval And Capital Raises Will Shape 2025 Outlook

Analysts have nudged their price target for Axogen slightly higher to reflect a modest uptick in fair value estimates to about $37.33. This move is supported by marginally stronger assumptions for profit margins and a slightly lower discount rate, while other pricing inputs, such as future P/E expectations, remain roughly in line with prior views.

AXGN: Q3 Execution And 2025 Outlook Will Support Higher Confidence

Analysts have nudged their fair value estimate for Axogen higher to US$37.00 from US$35.44, citing recent price target increases following Q3 outperformance and raised 2025 guidance as support for this updated view. Analyst Commentary Recent research updates cluster around Axogen's Q3 performance and refreshed 2025 outlook, with multiple price target revisions framing how analysts are thinking about valuation, growth, and execution risk.

AXGN: Q3 Execution Will Support Confidence In Raised 2025 Outlook

Analysts have nudged their average price target on Axogen higher, lifting it by a few dollars per share into the mid 20 dollar range. They cite the company's Q3 sales beat, increased 2025 growth outlook, and continued confidence in its market development strategy as key drivers of sustained revenue expansion.

AXGN: Market Development Progress Will Support Confidence In 2025 Outlook

Axogen's analyst price target has been raised materially, increasing from about $29 to roughly $35. Analysts cite a Q3 beat, an improved 2025 sales growth outlook of at least 19 percent year over year, and continued confidence that the company’s market development strategy will support faster revenue growth even as margins normalize.

AXGN: Execution And Upgraded Outlook Will Support Measured Momentum Ahead

Analysts have raised their price target for Axogen by $0.63 to $29.13, citing better-than-expected third-quarter performance and a strengthened sales outlook that is expected to drive anticipated growth in the coming years. Analyst Commentary Bullish analysts have responded positively to Axogen's recent performance and guidance updates.

Returns Are Gaining Momentum At Axogen (NASDAQ:AXGN)

Nov 27
Returns Are Gaining Momentum At Axogen (NASDAQ:AXGN)

AXGN: Strong Execution Will Drive Revenue Momentum With Upgraded 2025 Outlook

Axogen’s analyst price target has increased from $27.38 to $28.50 per share. Analysts cite strong quarterly results and higher fiscal 2025 growth guidance as supporting factors for this upward revision.

Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump

Nov 04
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump

AXGN: Strong Sales Momentum And Upcoming FDA Decision Will Drive Future Upside

Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.

Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet

Sep 12
Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet

Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story

Jul 23
Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story
User avatar

BLA Approval Will Secure 12-Year Exclusive Market Position

Anticipated product approval and targeted commercial expansion are driving increased market share, revenue growth, and improved profitability potential.

Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%

May 10
Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%

Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?

Apr 17
Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?

Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price

Mar 26
Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price

Is Axogen (NASDAQ:AXGN) Using Too Much Debt?

Jan 14
Is Axogen (NASDAQ:AXGN) Using Too Much Debt?

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Jan 07

Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 29% Price Jump

Dec 24
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 29% Price Jump

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Jul 29
A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

決済の安定と成長

配当データの取得

安定した配当: AXGNの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: AXGNの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Axogen 配当利回り対市場
AXGN 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (AXGN)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.2%
業界平均 (Medical Equipment)2.2%
アナリスト予想 (AXGN) (最長3年)n/a

注目すべき配当: AXGNは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: AXGNは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: AXGNの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: AXGNが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/03 13:33
終値2026/05/01 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Axogen, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
Caitlin CroninCanaccord Genuity
David TurkalyCitizens JMP Securities, LLC
Christopher PasqualeGuggenheim Securities, LLC